Timing, rates, and causes of death in a large South African tuberculosis programme

BMC Infectious Diseases

Pam Sonnenberg¹  Judith R Glynn²  Robert J Dowdeswell⁵  Jill Murray⁴  Megan SC Lim³  Nigel Field¹ 

[1] Research Department of Infection and Population Health, University College London, Mortimer Market Centre (off Capper St), London WC1E6JB, UK;Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK;Centre for Population Health, Burnet Institute, Melbourne, Australia;National Institute for Occupational Health, National Health Laboratory Service and School of Public Health, University of the Witwatersrand, Johannesburg, South Africa;Rustenburg Platinum Mines Limited, Rustenburg, South Africa

关键词: Autopsy;    Antiretroviral therapy (ART);    HIV;    Tuberculosis treatment;    Tuberculosis mortality;   

Others  :  1109773
DOI  :  10.1186/s12879-014-0679-9

 received in 2014-03-25, accepted in 2014-12-02,  发布年份 2014

【 摘 要 】

Background

Tuberculosis (TB) mortality remains high across sub-Saharan Africa despite integration of TB and HIV/ART programmes. To inform programme design and service delivery, we estimated mortality by time from starting TB treatment.

Methods

Routinely collected data on TB treatment, vital status, and the timing and causes of death, were linked to cardio-respiratory autopsy data, from 1995–2008, from a cohort of male platinum miners in South Africa. Records were expanded into person-months at risk (pm).

Results

4162 TB episodes were registered; 3170 men were treated for the first time and 833 men underwent retreatment. Overall, 509 men died, with a case fatality of 12.2% and mortality rate of 2.0/100 pm. Mortality was highest in the first month after starting TB treatment for first (2.3/100 pm) and retreatment episodes (4.8/100 pm). When stratified by HIV status, case fatality was higher in HIV positive men not on ART (first episode 14.0%; retreatment episode 26.2%) and those on ART (12.0%; 22.0%) than men of negative or unknown HIV status (2.6%; 3.6%). Mortality was also highest in the first month for each of these groups. Mortality risk factors included older age, previous TB, HIV, pulmonary TB, and diagnostic uncertainty. The proportion of deaths attributable to TB was consistently overestimated in clinical records versus cardio-respiratory autopsy.

Conclusions

Programme mortality was highest in those with HIV and during the first month of TB treatment in all groups, and many deaths were not caused by TB. Resource allocation should prioritise TB prevention and accurate earlier diagnosis, recognise the role of HIV, and ensure effective clinical care in the early stages of TB treatment.

【 授权许可】

   
2014 Field et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Statistics South Africa: Mortality and causes of death in South Africa, 2008: Findings from death notification. Statistics South Africa, Pretoria; 2010.
• [2]Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD: HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009, 374:921-933.
• [3]Lim MSC, Dowdeswell RJ, Murray J, Field N, Glynn JR, Sonnenberg P: The impact of HIV, an antiretroviral programme and tuberculosis on mortality in South African platinum miners, 1992–2010. PLoS One 2012, 7:e38598.
• [4]Corbett EL, Marston B, Churchyard GJ, De Cock KM: Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006, 367:926-937.
• [5]van den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomela A, Lefi M: Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tubercul Lung Dis 1998, 2:547-552.
• [6]Burton JL, Underwood J: Clinical, educational, and epidemiological value of autopsy. Lancet 2007, 369:1471-1480.
• [7]Connolly C, Davies GR, Wilkinson D: Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991–1995. Int J Tubercul Lung Dis 1998, 2:919-925.
• [8]Harries AD, Nyangulu DS, Kang'ombe C, Ndalama D, Glynn JR, Banda H, Wirima JJ, Salaniponi FM, Liomba G, Maher D, Nunn P: Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg 1998, 92:343-347.
• [9]Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM: High early death rate in tuberculosis patients in Malawi. Int J Tubercul Lung Dis 2001, 5:1000-1005.
• [10]Kang'ombe CT, Harries AD, Ito K, Clark T, Nyirenda TE, Aldis W, Nunn PP, Semba RD, Salaniponi FM: Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB. Int J Tubercul Lung Dis 2004, 8:829-836.
• [11]Kyeyune R, den Boon S, Cattamanchi A, Davis JL, Worodria W, Yoo SD, Huang L: Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr 2010, 55:446-450.
• [12]Elliott AM, Halwiindi B, Hayes RJ, Luo N, Mwinga AG, Tembo G, Machiels L, Steenbergen G, Pobee JO, Nunn P: The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg 1995, 89:78-82.
• [13]Mukadi YD, Maher D, Harries A: Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. Aids 2001, 15:143-152.
• [14]Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, Newnham R, Githui W, Gathua S, Omwega M, McAdam K: Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis 1992, 146:849-854.
• [15]Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H: Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009, 4:e7186.
• [16]Waitt CJ, Squire SB: A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tubercul Lung Dis 2011, 15:871-885.
• [17]Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P: Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999, 159:733-740.
• [18]Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM: Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tubercul Lung Dis 2000, 4:705-712.
• [19]Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK: Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis 2009, 15:258-264.
• [20]Korenromp EL, Bierrenbach AL, Williams BG, Dye C: The measurement and estimation of tuberculosis mortality. Int J Tubercul Lung Dis 2009, 13:283-303.
• [21]Sonnenberg P, Lim MSC, Dowdeswell R, Field N, Glynn JR, Murray J: Quantifying measurement errors in the estimation of tuberculosis mortality: lessons from a population of South African platinum miners. Int J Tubercul Lung Dis 2012, 16:1449-1454.
• [22]Mudenda V, Lucas S, Shibemba A, O'Grady J, Bates M, Kapata N, Schwank S, Mwaba P, Atun R, Hoelscher M, Maeurer M, Zumla A: Tuberculosis and Tuberculosis/HIV/AIDS-Associated Mortality in Africa: The Urgent Need to Expand and Invest in Routine and Research Autopsies. J Infect Dis 2012, 205:s340-s346.
• [23]Koole O, Colebunders R: ART in low-resource settings: how to do more with less. Lancet 2010, 376:396-398.
• [24]Charalambous S, Grant AD, Day JH, Pemba L, Chaisson RE, Kruger P, Martin D, Wood R, Brink B, Churchyard GJ: Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care 2007, 19:34-41.
• [25]Department of Health: National tuberculosis management guidelines 2008. Department of Health, Republic of South Africa, Pretoria; 2009.
• [26]Katzenstein A-LA: Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. (Major Prob Pathol vol. 13). 4th edition. Elsevier, Edinburgh; 2006.
• [27]World Health Organization: Global tuberculosis report 2013: Annex 1Methods, Table A1.2. WHO, Geneva; 2013.
• [28]Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D, Monkongdee P, Sitti W, Rienthong D, Siraprapasiri T, Wells CD, Tappero JW, Varma JK: Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007, 13:1001-1007.
• [29]Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, Hosseinipour M, Gummadi N: Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011, 6:e28691.
• [30]Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q: Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706.
• [31]Aderaye G, Bruchfeld J, Aseffa G, Nigussie Y, Melaku K, Woldeamanuel Y, Asrat D, Worku A, Gaegziabher H, Lebaad M, Lindquist L: Pneumocystis jiroveci pneumonia and other pulmonary infections in TB smear-negative HIV-positive patients with atypical chest X-ray in Ethiopia. Scand J Infect Dis 2007, 39:1045-1053.
• [32]Worodria W, Okot-Nwang M, Yoo SD, Aisu T: Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. Int J Tubercul Lung Dis 2003, 7:117-123.
• [33]Martinson NA, Karstaedt A, Venter WD, Omar T, King P, Mbengo T, Marais E, McIntyre J, Chaisson RE, Hale M: Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS 2007, 21:2043-2050.
• [34]Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, Eiger O, Shiraishi R, Marston B, Ellerbrock T, Libamba E: Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 2007, 46:56-61.
• [35]Hoffmann CJ, Fielding KL, Charalambous S, Innes C, Chaisson RE, Grant AD, Churchyard GJ: Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. Aids 2010, 24:1709-1716.
• [36]Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM, Greenberg AE: Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999, 353:1469-1475.
• [37]Jonnalagada S, Harries AD, Zachariah R, Satyanarayana S, Tetali S, Keshav Chander G, Rao S, Rao R, Peri S, Anchala R, Kannuri NK: The timing of death in patients with tuberculosis who die during anti-tuberculosis treatment in Andhra Pradesh, South India. BMC Public Health 2011, 11:921. BioMed Central Full Text
• [38]Chaisson RE, Churchyard GJ: Recurrent tuberculosis: relapse, reinfection, and HIV. J Infect Dis 2010, 201:653-655.
• [39]Glynn JR, Warndorff DK, Fine PE, Munthali MM, Sichone W, Ponnighaus JM: Measurement and determinants of tuberculosis outcome in Karonga District, Malawi. Bull World Health Organ 1998, 76:295-305.
• [40]Field N, Murray J, Wong ML, Dowdeswell R, Dudumayo N, Rametsi L, Martinson N, Lipman M, Glynn JR, Sonnenberg P: Missed opportunities in TB diagnosis: a TB Process-Based Performance Review tool to evaluate and improve clinical care. BMC Public Health 2011, 11:127. BioMed Central Full Text
• [41]Cowie RL: The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 1994, 150:1460-1462.
• [42]Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godrey-Faussett P: HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001, 357:890.